A brief summary of recent clinical advances in Hodgkin lymphoma abstracted from the 55th ASH annual meeting
10.3760/cma.j.issn.1009-9921.2013.12.001
- VernacularTitle:第55届美国血液学会年会有关霍奇金淋巴瘤的最新研究概况
- Author:
Yongqian JIA
- Publication Type:Journal Article
- Keywords:
Lymphoma,Hodgkin;
ASH annual meeting
- From:
Journal of Leukemia & Lymphoma
2013;22(12):705,716-
- CountryChina
- Language:Chinese
-
Abstract:
The 55th ASH annual meeting hold special education sessions and oral and poster presentations focused on Hodgkin lymphoma (HL).Experts from world around made highly of the monoclonal antibody to CD30 (BV),for it' s effectiveness on refractory or relapsed HL.The targeted chemotherapy which integrated BV with standard chemotherapy appeared promising as first line therapy in a few centers.The applications of other molecular inhibitors,anti-CD20 antibody and involved field radiation therapy had been discussed.A broad presentations and discussions had been made on HL of the gene expression profiling,molecular susceptibilities,the long non-coding RNA,the miRNA,the molecular diagnosis with peripheral blood,as well as prognosis related factors.
